Facebook
Twitter
Telegram
Report an ErrorAkari Therapeutics, Plc Financial Ratios 2011-2024 | AKTX
Annual Financial Ratios Akari Therapeutics, Plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1829.1 | -1199.6 | -369.5 | -342.1 | -190.2 | -146.9 | -152.6 | -441.4 | -260.2 | -3.3 | -5.9 | - | - |
P/S |
- | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
- | - | - | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.1 | -0.2 | -0.2 | -0.3 | -0.2 |
EV (Enterprise Value) |
18.3 B | 21.3 B | 6.44 B | 5.84 B | 3.21 B | 2.42 B | 5.38 B | 7.99 B | 11.7 B | 29.7 M | 23 M | 3.38 M | 2.51 M |
EBITDA per Share |
- | - | - | -0.01 | -0.01 | -0.01 | -0.03 | -0.0231 | -0.0628 | -18.8 | -17.3 | - | - |
EV/EBITDA |
-249.4 | -244.6 | -195.3 | -154.1 | -94.8 | -293.1 | -218.9 | -2.5 | -3.8 | - | - | ||
PEG |
13.5 | 17.1 | 4.76 | -3.0 | 1.21 | -6.21 | -2.61 | 0.55 | 0.19 | - | - | ||
P/B |
-79936.2 | 11889.0 | 1159.1 | 622.8 | -1807.8 | 777.3 | 314.9 | 234.8 | 242.0 | 6.5 | 3.7 | - | - |
P/CF |
-1114.0 | -990.0 | -341.6 | -344.8 | -248.0 | -107.1 | -170.9 | -324.5 | -2369.5 | -3.3 | -3.9 | - | - |
ROE % |
4370.31 | -991.10 | -313.69 | -182.02 | -221718.91 | -529.26 | -206.36 | -53.20 | -93.02 | -198.80 | -62.26 | - | - |
ROA % |
-229.80 | -128.32 | -149.59 | -116.96 | -247.67 | -205.08 | -121.86 | -39.55 | -64.84 | -148.89 | -46.22 | - | - |
ROCE % |
7338.86 | -1289.31 | -309.91 | -191.61 | -223257.70 | -642.55 | -219.62 | -79.76 | -109.82 | -198.73 | -54.63 | - | - |
Current Ratio |
1.0 | 1.1 | 1.9 | 2.8 | 0.8 | 1.6 | 2.4 | 3.9 | 3.3 | 4.7 | 6.4 | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Akari Therapeutics, Plc
| 2024-Q1 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01 | - | - | - | - | - | - | - | -0.01 | -0.003 | - | -0.06 | -0.002 | -0.002 | - | - | -0.04 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01 | - | - | - | -0.01 | - | - | - | -0.01 | - | - | -0.03 | - | - | - | - | -0.04 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
187.17 | 15.26 | 15.26 | - | - | -273.70 | -547.40 | -547.40 | -260.55 | -247.41 | -98.59 | -226.32 | -285.11 | -357.04 | -1526.93 | -1357.41 | -1357.41 | -1391.62 | -189.84 | -185.98 | -92.99 | -94.39 | -2.80 | -2.80 | -1.40 | -17.30 | -31.79 | -38.23 | -140.25 | -258.16 | -380.07 | -259.19 | -269.23 | -161.35 | -69.49 | -254.77 | -254.77 | -244.74 | -198.80 | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-200.79 | - | - | - | - | -89.99 | -179.99 | -179.99 | -83.32 | -76.65 | -38.14 | -83.50 | -111.57 | -146.30 | -223.78 | -159.29 | -159.29 | -178.08 | -95.99 | -93.72 | -46.86 | -47.86 | -2.00 | -2.00 | -1.00 | -12.19 | -22.39 | -27.13 | -77.49 | -139.05 | -173.15 | -109.28 | -115.85 | -60.87 | -49.97 | -189.86 | -189.86 | -183.29 | -148.89 | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | - | - | - | - | -272.67 | -545.35 | -545.35 | -276.23 | -279.78 | -106.34 | -253.52 | -317.11 | -377.14 | -1590.90 | -1376.33 | -1376.33 | -1403.00 | -180.27 | -180.52 | -90.26 | -122.34 | -64.16 | -64.16 | -32.08 | -50.58 | -37.01 | -45.31 | -83.18 | -139.56 | -186.65 | -125.37 | -135.18 | -88.61 | -68.50 | -92.08 | -92.08 | -82.27 | -36.77 | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | - | - | - | 1.9 | - | 1.5 | - | 2.8 | 2.0 | 1.7 | 1.5 | 1.0 | 1.9 | 1.1 | 2.4 | 1.6 | - | 2.0 | - | 2.4 | - | 3.5 | - | 3.9 | - | 3.4 | 3.8 | 3.3 | 2.1 | - | 3.3 | 2.9 | 2.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency